NCT06906341 2026-04-14Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersCorcept TherapeuticsPhase 2 Recruiting270 enrolled
NCT05281471 2026-03-18Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)Genelux CorporationPhase 3 Recruiting186 enrolled
NCT03776812 2025-10-07Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerCorcept TherapeuticsPhase 2 Completed178 enrolled 21 charts
NCT05257408 2025-04-16Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerCorcept TherapeuticsPhase 3 Active not recruiting381 enrolled 3 FDA
NCT02658214 2020-08-20Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsAstraZenecaPhase 1 Completed32 enrolled
NCT01478685 2019-11-12A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid TumorsCelgenePhase 1 Completed169 enrolled